0IL Stock Overview
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
IntelGenx Technologies Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$0.19 |
| 52 Week Low | US$0.061 |
| Beta | 2.48 |
| 1 Month Change | -18.52% |
| 3 Month Change | 12.82% |
| 1 Year Change | -13.16% |
| 3 Year Change | -70.93% |
| 5 Year Change | -70.47% |
| Change since IPO | -79.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IL | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -10.8% | 3.2% | 1.7% |
| 1Y | -13.2% | -28.2% | 2.3% |
Return vs Industry: 0IL exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: 0IL underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 0IL volatility | |
|---|---|
| 0IL Average Weekly Movement | 31.3% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0IL's share price has been volatile over the past 3 months.
Volatility Over Time: 0IL's weekly volatility has increased from 25% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Dwight Gorham | www.intelgenx.com |
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression.
IntelGenx Technologies Corp. Fundamentals Summary
| 0IL fundamental statistics | |
|---|---|
| Market cap | €26.75m |
| Earnings (TTM) | -€9.28m |
| Revenue (TTM) | €970.84k |
25.2x
P/S Ratio-2.6x
P/E RatioIs 0IL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IL income statement (TTM) | |
|---|---|
| Revenue | US$1.04m |
| Cost of Revenue | US$1.73m |
| Gross Profit | -US$694.00k |
| Other Expenses | US$9.23m |
| Earnings | -US$9.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | -66.80% |
| Net Profit Margin | -955.44% |
| Debt/Equity Ratio | -121.6% |
How did 0IL perform over the long term?
See historical performance and comparison